Clinical Trial Update: A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating atezolizumab as adjuvant therapy after definitive local therapy in high-risk locally advanced squamous cell carcinoma of the head and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 3 | Status: TERMINATED | Results posted: 2024-10-09